Biogen and Xbrane Biopharma (Xbrane) have announced a commercialization and licensing agreement for a biosimilar of certolizumab pegol (Cimzia), which can be used to treat rheumatoid arthritis and other inflammatory conditions.
On 7 February 2022, US-based Biogen and Sweden-based Xbrane announced an agreement to develop, manufacture and commercialize a proposed biosimilar of certolizumab pegol (Cimzia, UCB). UCB’s patent on Cimzia in the EU expired in 2021 and is set to expire in the US in 2024.
Certolizumab pegol is a monoclonal antibody targeting the inflammatory molecule tumour necrosis factor-alpha (TNF-alpha). It is primarily used to treat rheumatoid arthritis but can also be used to treat other inflammatory conditions including axial spondylarthrosis, psoriasis, and Crohn’s disease.
The proposed biosimilar will be sold under the brand name Xcimzane. Under the terms of the agreement, Xbrane will be responsible for preclinical development of Xcimzane while Biogen will have exclusive global regulatory, manufacturing and commercial rights to the biosimilar and will be Marketing Authorization Holder.
Biogen will make an upfront payment to Xbrane. If development and commercial milestones are achieved, Xbrane will be eligible to receive milestone payments, as well as tiered royalties.
Ian Henshaw, Head of Global Biosimilars at Biogen, said: ‘[…We] are excited to bring this additional asset to our Biosimilars pipeline. This preclinical biosimilar candidate has the potential to add another option for patients living with Rheumatoid Arthritis and other indications’.
Martin Åmark, CEO of Xbrane, added: ‘Given their vast development and commercialization experience, we are convinced that Biogen is the best possible partner we could have for Xcimzane. Today’s announcement confirms Xbrane’s ambition to become a global biosimilar developer’.
In related news, Biogen recently sold its stake in Samsung Bioepis to Samsung Biologics, freeing up capital for acquisitions [1]. However, Biogen will retain commercial rights for Byooviz (ranibizumab-nuna), which was approved in Europe in August 2021 [2], and be able to commercialize the investigational biosimilar candidate SB15 (aflibercept).
Related article
STADA and Xbrane strengthen biosimilars collaboration
| LATIN AMERICAN FORUM The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View last week’s headline article: Nomenclatura de biológicos y biosimilares en Brasil Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative. LATIN AMERICAN FORUM Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Vea el artículo principal de la semana pasada: Nomenclatura de biológicos y biosimilares en Brasil iExplore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.
|
References
1. GaBI Online - Generics and Biosimilars Initiative. Samsung to take full control of Samsung Bioepis [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Mar 4]. Available from: www.gabionline.net/pharma-news/samsung-to-take-full-control-of-samsung-bioepis
2. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of Samsung Bioepis/Biogen’s ranibizumab biosimilar Byooviz [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Mar 4]. Available from: www.gabionline.net/biosimilars/news/ema-recommends-approval-of-samsung-bioepis-biogen-s-ranibizumab-biosimilar-byooviz
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.
0
Post your comment